A quinolin-8-ol sub-millimolar inhibitor of UGGT, the ER glycoprotein folding quality control checkpoint
Guay KP., Ibba R., Kiappes JL., Vasiljevic S., Boni F., De Benedictis M., Zeni I., Le Cornu JD., Hensen M., Chandran AV., Kantsadi AL., Caputo AT., Blanco Capurro JI., Bayo Y., Hill JC., Hudson K., Lia A., Brun J., Withers SG., Martí M., Biasini E., Santino A., De Rosa M., Milani M., Modenutti CP., Hebert DN., Zitzmann N., Roversi P.
Misfolded glycoprotein recognition and endoplasmic reticulum (ER) retention are mediated by the ER glycoprotein folding Quality Control (ERQC) checkpoint enzyme, UDP-Glucose glycoprotein glucosyltransferase (UGGT). UGGT modulation is a promising strategy for broad-spectrum antivirals, rescue-of-secretion therapy in rare disease caused by responsive mutations in glycoprotein genes, and many cancers, but to date no selective UGGT inhibitors are known. We carried out a fragment-based lead discovery screen via X-ray crystallography and discovered that the small molecule 5-[(morpholin4-yl)methyl]quinolin-8-ol (5M-8OH-Q) binds a CtUGGTGT24 ‘WY’ conserved surface motif conserved across UGGTs but not present in other GT24 family glycosyltransferases. 5M-8OH-Q has a 47 µM binding affinity for human UGGT1 in vitro as measured by ligand-enhanced fluorescence. In cellula, 5M8OH-Q inhibits both human UGGT isoforms at concentrations higher than 750 µM. 5M-8OH-Q likely binds to the site of recognition of the first GlcNAc residue of the substrate N -glycan. 5M-8OH-Q binding to CtUGGTGT24 appears to be mutually exclusive to M5-9 glycan binding in an in vitro competition experiment. A medicinal program based on 5M-8OH-Q will yield the next generation of UGGT inhibitors.